Payment overview · 2025
General Payments
$1,140.17
70 reported records · 22 companies
Healthcare provider profile · identity verified
Javed Iqbal, MD
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · LAS CRUCES, NM · NPI 1235123605
Verified facts
What the public records show
CMS Open Payments records show Javed Iqbal, MD received $1,140.17 in general payments during 2025 across 70 reported records.
ABBVIE INC. accounted for 16.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 26 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Botox, Fycompa, Ingrezza, Nayzilam, Nurtec Odt, Qulipta, Rexulti, Ubrelvy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BOTOX as an associated drug or biological on 140321 records involving 30103 distinct recipient NPIs. Public Medicare Part D data also shows 189 claims for Botox by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Ubrelvy by this doctor in 2024.
Amneal Pharmaceuticals LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RYTARY as an associated drug or biological on 200 records involving 121 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Rytary by this doctor in 2024.
CATALYST PHARMACEUTICALS, INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FYCOMPA as an associated drug or biological on 3130 records involving 1101 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Fycompa by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Rexulti by this doctor in 2024.
Neurocrine BioSciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INGREZZA as an associated drug or biological on 126456 records involving 27390 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Ingrezza by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Nurtec Odt by this doctor in 2024.
SK Life Science, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XCOPRI as an associated drug or biological on 1992 records involving 782 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Xcopri by this doctor in 2024.
UCB, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Briviact as an associated drug or biological on 13595 records involving 4444 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Briviact by this doctor in 2024.
UCB, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Nayzilam as an associated drug or biological on 9542 records involving 3826 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Nayzilam by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $188.36 | 16.5% | 14 | 2025 |
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $103.61 | 9.1% | 3 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $96.41 | 8.5% | 6 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $93.32 | 8.2% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $63.70 | 5.6% | 4 | 2025 |
| Merz Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $61.90 | 5.4% | 4 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $61.48 | 5.4% | 4 | 2025 |
| TG Therapeutics, Inc. | Unresolved — no canonical attribution shown | $60.63 | 5.3% | 4 | 2025 |
| CSL Behring | Unresolved — no canonical attribution shown | $49.68 | 4.4% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $47.70 | 4.2% | 3 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $45.58 | 4.0% | 3 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $44.12 | 3.9% | 3 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$43.19 | 3.8% | 3 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $32.18 | 2.8% | 2 | 2025 |
| CATALYST PHARMACEUTICALS, INC. | Unresolved — no canonical attribution shown | $30.35 | 2.7% | 2 | 2025 |
| SpringWorks Therapeutics, Inc. | Unresolved — no canonical attribution shown | $18.95 | 1.7% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $18.25 | 1.6% | 1 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $18.25 | 1.6% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $16.90 | 1.5% | 1 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $16.79 | 1.5% | 1 | 2025 |
| Neurelis, Inc. |
Neurelis, Inc. exact · evidence 2025-02-20 |
$14.83 | 1.3% | 1 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $13.99 | 1.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,070.18 | 69 |
| Education | $69.99 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $188.36 | 14 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $158.27 | 12 | 2025 |
Source payment records
|
|||||
| VUMERITY Normalized: vumerity |
Drug | Biogen, Inc. | $96.41 | 6 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $63.70 | 4 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $63.70 | 4 | 2025 |
Source payment records
|
|||||
| Xeomin Normalized: xeomin |
Biological | Merz Pharmaceuticals, LLC | $61.90 | 4 | 2025 |
Source payment records
|
|||||
| BRIUMVI Normalized: briumvi |
Drug | TG Therapeutics, Inc. | $60.63 | 4 | 2025 |
Source payment records
|
|||||
| Fintepla Normalized: fintepla |
Drug | UCB, Inc. | $57.68 | 3 | 2025 |
Source payment records
|
|||||
| Hizentra Normalized: hizentra |
Biological | CSL Behring | $49.68 | 3 | 2025 |
Source payment records
|
|||||
| INBRIJA Normalized: inbrija |
Drug | Merz Pharmaceuticals, LLC | $45.87 | 3 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $45.58 | 3 | 2025 |
Source payment records
|
|||||
| Ocrevus Zunovo Normalized: ocrevus zunovo |
Biological | Genentech USA, Inc. | $45.32 | 3 | 2025 |
Source payment records
|
|||||
| CREXONT Normalized: crexont |
Drug | Amneal Pharmaceuticals LLC | $44.12 | 3 | 2025 |
Source payment records
|
|||||
| Nayzilam Normalized: nayzilam |
Drug | UCB, Inc. | $35.64 | 2 | 2025 |
Source payment records
|
|||||
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $33.62 | 2 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $32.18 | 2 | 2025 |
Source payment records
|
|||||
| FYCOMPA Normalized: fycompa |
Drug | CATALYST PHARMACEUTICALS, INC. | $30.35 | 2 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $30.09 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $29.38 | 2 | 2025 |
Source payment records
|
|||||
| GOMEKLI Normalized: gomekli |
Drug | SpringWorks Therapeutics, Inc. | $18.95 | 1 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $18.32 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $18.25 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $16.90 | 1 | 2025 |
Source payment records
|
|||||
| Enspryng Normalized: enspryng |
Biological | Genentech USA, Inc. | $16.16 | 1 | 2025 |
Source payment records
|
|||||
| VALTOCO Normalized: valtoco |
Drug | Neurelis, Inc. | $14.83 | 1 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $13.99 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| BOTOX botox |
2025 | Botox | 2024 | 189 | exact normalized | Medicare Part D |
| FYCOMPA fycompa |
2025 | Fycompa | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| INGREZZA ingrezza |
2025 | Ingrezza | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Nayzilam nayzilam |
2025 | Nayzilam | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 69 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | BOTOX open payments reported associated product |
CMS Open Payments — General Payments 140321 supporting records · 30103 recipient NPIs · example record 1201352642 |
Botox · 2024 Exact normalized brand match · 1 Part D row |
189 | 65 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
69 | suppressed by CMS |
| Amneal Pharmaceuticals LLC Exact reporting entity; no affiliate inference |
2025 | RYTARY open payments reported associated product |
CMS Open Payments — General Payments 200 supporting records · 121 recipient NPIs · example record 1220526035 |
Rytary · 2024 Exact normalized brand match · 1 Part D row |
83 | 18 |
| CATALYST PHARMACEUTICALS, INC. Exact reporting entity; no affiliate inference |
2025 | FYCOMPA open payments reported associated product |
CMS Open Payments — General Payments 3130 supporting records · 1101 recipient NPIs · example record 1253216846 |
Fycompa · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Neurocrine BioSciences, Inc. Exact reporting entity; no affiliate inference |
2025 | INGREZZA open payments reported associated product |
CMS Open Payments — General Payments 126456 supporting records · 27390 recipient NPIs · example record 1242766729 |
Ingrezza · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| SK Life Science, Inc. Exact reporting entity; no affiliate inference |
2025 | XCOPRI open payments reported associated product |
CMS Open Payments — General Payments 1992 supporting records · 782 recipient NPIs · example record 1252276115 |
Xcopri · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| UCB, Inc. Exact reporting entity; no affiliate inference |
2025 | Briviact open payments reported associated product |
CMS Open Payments — General Payments 13595 supporting records · 4444 recipient NPIs · example record 1224348489 |
Briviact · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| UCB, Inc. Exact reporting entity; no affiliate inference |
2025 | Nayzilam open payments reported associated product |
CMS Open Payments — General Payments 9542 supporting records · 3826 recipient NPIs · example record 1224348539 |
Nayzilam · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Donepezil Hcl | Donepezil Hcl | 1445 | 383 |
| Memantine Hcl | Memantine Hcl | 1317 | 323 |
| Levetiracetam | Levetiracetam | 722 | 156 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 537 | 128 |
| Gabapentin | Gabapentin | 524 | 123 |
| Topiramate | Topiramate | 423 | 103 |
| Divalproex Sodium Er | Divalproex Sodium | 395 | 112 |
| Divalproex Sodium | Divalproex Sodium | 361 | 97 |
| Baclofen | Baclofen | 320 | 74 |
| Oxcarbazepine | Oxcarbazepine | 268 | 75 |
| Primidone | Primidone | 243 | 55 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 238 | 83 |
| Lamotrigine | Lamotrigine | 209 | 46 |
| Clonazepam | Clonazepam | 201 | 33 |
| Lacosamide | Lacosamide | 197 | 25 |
| Nortriptyline Hcl | Nortriptyline Hcl | 190 | 53 |
| Botox | Onabotulinumtoxina | 189 | 65 |
| Phenobarbital | Phenobarbital | 166 | 26 |
| Propranolol Hcl | Propranolol Hcl | 142 | 36 |
| Aimovig Autoinjector | Erenumab-Aooe | 140 | 24 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 139 | 41 |
| Ropinirole Hcl | Ropinirole Hcl | 128 | 28 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 127 | 31 |
| Sumatriptan Succinate | Sumatriptan Succinate | 127 | 48 |
| Pregabalin | Pregabalin | 126 | 34 |
| Amantadine | Amantadine Hcl | 112 | 30 |
| Sertraline Hcl | Sertraline Hcl | 111 | 25 |
| Carbamazepine | Carbamazepine | 110 | 22 |
| Rizatriptan | Rizatriptan Benzoate | 109 | 36 |
| Amitriptyline Hcl | Amitriptyline Hcl | 108 | 27 |
| Carbamazepine Er | Carbamazepine | 101 | 23 |
| Doxepin Hcl | Doxepin Hcl | 93 | 24 |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 89 | 19 |
| Propranolol Hcl Er | Propranolol Hcl | 87 | 17 |
| Alprazolam | Alprazolam | 84 | 14 |
| Rytary | Carbidopa/Levodopa | 83 | 18 |
| Zonisamide | Zonisamide | 78 | 13 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 75 | 16 |
| Ubrelvy | Ubrogepant | 69 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 67 | 15 |
| Risperidone | Risperidone | 64 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 61 | 17 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 59 | suppressed |
| Prednisone | Prednisone | 57 | 18 |
| Meclizine Hcl | Meclizine Hcl | 54 | 16 |
| Emgality Pen | Galcanezumab-Gnlm | 52 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 52 | suppressed |
| Diazepam | Diazepam | 51 | 14 |
| Galantamine Er | Galantamine Hbr | 51 | 11 |
| Ibuprofen | Ibuprofen | 49 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 48 | 21 |
| Aptiom | Eslicarbazepine Acetate | 44 | suppressed |
| Lorazepam | Lorazepam | 43 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 42 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 41 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 38 | suppressed |
| Acetazolamide | Acetazolamide | 35 | 17 |
| Verapamil Er | Verapamil Hcl | 35 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 33 | suppressed |
| Entacapone | Entacapone | 31 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 31 | suppressed |
| Ondansetron Odt | Ondansetron | 30 | 13 |
| Xcopri | Cenobamate | 30 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 28 | suppressed |
| Valproic Acid | Valproic Acid | 28 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 27 | suppressed |
| Dimethyl Fumarate | Dimethyl Fumarate | 25 | suppressed |
| Teriflunomide | Teriflunomide | 25 | suppressed |
| Butorphanol Tartrate | Butorphanol Tartrate | 24 | suppressed |
| Fycompa | Perampanel | 24 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 24 | suppressed |
| Modafinil | Modafinil | 23 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 23 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 21 | suppressed |
| Clobazam | Clobazam | 20 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 20 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Indomethacin | Indomethacin | 19 | suppressed |
| Ropinirole Er | Ropinirole Hcl | 19 | suppressed |
| Butalb-Acetaminoph-Caff-Codein | Butalbit/Acetamin/Caff/Codeine | 18 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 18 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 17 | suppressed |
| Mayzent | Siponimod | 17 | suppressed |
| Naratriptan Hcl | Naratriptan Hcl | 17 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 17 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 16 | suppressed |
| Butalbital-Aspirin-Caffeine | Butalbital/Aspirin/Caffeine | 15 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 15 | suppressed |
| Donepezil Hcl Odt | Donepezil Hcl | 15 | suppressed |
| Ethosuximide | Ethosuximide | 15 | suppressed |
| Nayzilam | Midazolam | 15 | suppressed |
| Sumatriptan | Sumatriptan | 15 | suppressed |
| Dalfampridine Er | Dalfampridine | 14 | suppressed |
| Glatopa | Glatiramer Acetate | 14 | suppressed |
| Ingrezza | Valbenazine Tosylate | 14 | suppressed |
| Rexulti | Brexpiprazole | 14 | suppressed |
| Austedo | Deutetrabenazine | 13 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 13 | suppressed |
| Lamictal | Lamotrigine | 13 | suppressed |
| Meloxicam | Meloxicam | 13 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 13 | suppressed |
| Mirtazapine | Mirtazapine | 13 | suppressed |
| Qulipta | Atogepant | 13 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 12 | suppressed |
| Briviact | Brivaracetam | 12 | suppressed |
| Lamotrigine Er | Lamotrigine | 12 | suppressed |
| Dextroamphetamine Sulfate Er | Dextroamphetamine Sulfate | 11 | suppressed |
| Fingolimod | Fingolimod Hcl | 11 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 11 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 11 | suppressed |
| Zolmitriptan Odt | Zolmitriptan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,140.17 · 70 records | ABBVIE INC. | BOTOX, BRIUMVI, CREXONT, Enspryng, FYCOMPA, Fintepla, GOMEKLI, Hizentra, INBRIJA, INGREZZA, Leqembi, NUPLAZID, NURTEC ODT, Nayzilam, Ocrevus Zunovo, QULIPTA, REXULTI, UBRELVY, ULTOMIRIS, VALTOCO, VUMERITY, VYEPTI, VYVGART HYTRULO, WAKIX, Xeomin, ZAVZPRET | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Botox play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error